- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00086866
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
Randomized, Open Phase II Study of Immunization With the Recombinant MAGE-3 Protein Combined With Adjuvant AS02B or AS15 in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying two different regimens of vaccine therapy and comparing them to see how well they work in treating patients with stage III or stage IV melanoma that cannot be removed with surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Compare the objective response rate (complete and partial response) in patients with unresectable stage III or stage IV M1a cutaneous melanoma immunized with vaccine comprising D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant vs SB-AS15 adjuvant.
- Compare the activity of SB-AS02B adjuvant vs SB-AS15 adjuvant, in terms of maximizing the antigenicity of MAGE-3, in patients treated with these regimens.
- Compare the rate of grade 3/4 vaccine-related toxicity in patients treated with these regimens.
Secondary
- Compare progression-free survival in patients treated with these regimens.
OUTLINE: This is a randomized, open label, parallell-group, multicenter study. Patients are stratified according to disease stage (III in transit vs other stage III vs IV), presence of lesion ≥ 20 mm (yes vs no), and participating center. Patients are randomized to 1 of 2 treatment arms.
Induction therapy
- Arm I: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant intramuscularly (IM) once weekly on weeks 1, 3, 5, 7, 9, and 11.
- Arm II: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein SB-AS15 adjuvant IM once weekly on weeks 1, 3, 5, 7, 9, and 11.
Patients achieving a clinical complete response (CR), partial response (PR), stable disease (SD), or slow progressive disease (SPD) proceed to maintenance therapy.
- Maintenance therapy: Patients in both arms receive immunization (according to their randomized arm) once weekly on weeks 15, 18, 21, 24, 27, 30, 34, 40, 46, and 52.
Patients maintaining a CR, PR, or SD proceed to long-term treatment.
- Long-term treatment: Beginning 3 months after completion of maintenance therapy, patients in both arms receive immunization (according to their randomized arm) once every 3 months for 4 courses and then once every 6 months for 4 courses.
Treatment continues in both arms in the absence of disease progression that does not correspond to SPD status, unacceptable toxicity, or the diagnosis of an autoimmune disease.
Patients are followed every 12 weeks.
PROJECTED ACCRUAL: A total of 68 patients (34 patients per treatment arm) will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1000
- Institut Jules Bordet
-
Brussels, Belgium, 1070
- Hopital Universitaire Erasme
-
-
-
-
-
Hyeres, France, 83400
- Clinique Sainte-Marguerite
-
Lille, France, 59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Montpellier, France, 34295
- Hopital St. Eloi
-
Nantes, France, 44093
- CHR Hotel Dieu
-
Paris, France, 75248
- Institut Curie Hopital
-
Villejuif, France, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Berlin, Germany, D-12200
- Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
-
Mannheim, Germany, D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg, Germany, D-97080
- Universitaets - Kinderklinik Wuerzburg
-
-
-
-
-
Aviano, Italy, 33081
- Centro di Riferimento Oncologico - Aviano
-
Naples, Italy, 80131
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Padova, Italy, 35128
- Azienda Ospedaliera di Padova
-
Siena, Italy, 53100
- Universita di SIENA
-
-
-
-
-
Leiden, Netherlands, 2300 RC
- Leiden University Medical Center
-
Rotterdam, Netherlands, 3008 AE
- Daniel Den Hoed Cancer Center at Erasmus Medical Center
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona
-
Madrid, Spain, 28041
- Hospital Universitario 12 De Octubre
-
-
-
-
England
-
London, England, United Kingdom, EC1A 7BE
- Saint Bartholomew's Hospital
-
Manchester, England, United Kingdom, M20 4BX
- Christie Hospital NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed cutaneous melanoma
- Unresectable stage III OR stage IV M1a disease
- Documented progressive disease within the past 12 weeks
- Measurable disease
- Skin, soft tissue, or lymph node metastasis allowed provided the disease is not amenable to curative treatment with surgery
- Tumor must express the MAGE-3 gene by reverse transcription polymerase chain reaction analysis (more than 1% of the positive MAGE-3 control included in the assay)
- No visceral metastases within the past 56 days by imaging
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Hemoglobin ≥ lower limit of normal (LLN)
- WBC ≥ LLN
- Lymphocyte count ≥ LLN
- Platelet count ≥ LLN
- No bleeding disorders
Hepatic
- Bilirubin ≤ upper limit of normal (ULN)
- Lactic dehydrogenase ≤ ULN
- AST and ALT ≤ 2 times ULN
- PT and aPTT normal
- Hepatitis B surface antigen negative (antibody test may be positive)
- Hepatitis C antibody negative
Renal
- Creatinine ≤ ULN
Cardiovascular
- No clinically significant heart disease (CTC grade III or IV)
Immunologic
- No autoimmune disease (vitiligo allowed)
- No anti-nuclear antibody titer ≥ 1/320 OR equal to 1/160 AND auto-antibodies directed against specific auto-antigens
- No immunodeficiency
- No active infection requiring antibiotic therapy
- HIV negative
Other
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study participation
- No other malignancy within the past 5 years except surgically cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No other serious acute or chronic illness requiring concurrent medications
- No psychological, familial, sociological, or geographical condition that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 8 weeks since prior adjuvant vaccine therapy
- No prior vaccine therapy containing a MAGE-3 antigen
- No prior vaccine therapy for metastatic melanoma
- No concurrent immunomodulating agents (e.g., BCG)
Chemotherapy
- No prior systemic chemotherapy
- No concurrent chemotherapy
Endocrine therapy
No concurrent corticosteroids
- Concurrent prednisone or equivalent allowed provided the dose is ≤ 40 mg/day and treatment duration is for no more than 3 weeks
- Concurrent inhaled and topical steroids are allowed
Radiotherapy
- No prior radiotherapy to the spleen
No concurrent radiotherapy to > 20% of all existing lesions (i.e., target lesions, non-target lesions, and nonmeasurable lesions)
- Concurrent local low-dose (≤ 20 Grays) radiotherapy allowed
Surgery
- Recovered from prior surgery or biopsy
- No prior organ allograft
- No prior splenectomy
- Concurrent surgery to a limited number of lesions allowed for patients with a complete response, partial response, or stable disease after at least 3 courses of study therapy
Other
- No prior systemic anticancer therapy
- More than 4 weeks since prior isolated limb perfusion therapy
- No other concurrent anticancer therapy
- No other concurrent immunosuppressive agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Response rate (complete response and partial response) as assessed by RECIST criteria
|
Vaccine-related toxicity as assessed by CTCAE v3
|
Secondary Outcome Measures
Outcome Measure |
---|
Progression-free survival
|
Rate of stabilization as assessed by RECIST criteria
|
Rate of mixed response as assessed by RECIST criteria
|
Rate of immune response
|
Collaborators and Investigators
Investigators
- Study Chair: Willem H. J. Kruit, MD, PhD, Daniel Den Hoed Cancer Center at Erasmus Medical Center
Publications and helpful links
General Publications
- Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.
- Kruit WH, Suciu S, Dreno B, et al.: Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9065, 2008.
- Louahed J, Gruselle O, Gaulis S, et al.: Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9045, 2008.
- Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EORTC-16032-18031
- EORTC-18031
- EORTC-16032
- GSK-249553/008
- 2004-001937-40 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma (Skin)
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
William CarsonSchering-PloughCompletedStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin MelanomaUnited States
-
Roswell Park Cancer InstituteCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin MelanomaUnited States, Australia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte Corporation; University of VirginiaCompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin MelanomaUnited States
Clinical Trials on D1/3-MAGE-3-His fusion protein
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Charite University, Berlin, GermanyUnknown
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
University of ChicagoCompletedMetastatic MelanomaUnited States
-
Ludwig Institute for Cancer ResearchTerminated
-
Emory UniversityGeorgia Center for Oncology Research & EducationNot yet recruitingHuman Immunodeficiency Virus | Human Papilloma Virus | Anal Intraepithelial Neoplasia | High-Grade Squamous Intraepithelial LesionsUnited States
-
Cliniques universitaires Saint-Luc- Université...Terminated
-
M.D. Anderson Cancer CenterCompleted
-
Charite University, Berlin, GermanyBiogenCompleted